A combination of PBM and a static magnetic field exerted neuroprotective effects by reducing GFAP and Iba1 expression, oxidative stress, and apoptosis, following their increase through the injection of Aβ25-35 peptide, which causes Alzheimer’s disease; overall, the treatment appeared to improve memory [44]. Here, GFAP is linked to early-onset autosomal dominant Alzheimer disease.